Clinical Trial Update: A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating avutometinib, defactinib, and letrozole in patients with low-grade serous ovarian cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Serous Ovarian Cancer

Drugs mentioned

• Avutometinib (avutometinib)
• Defactinib (defactinib)
• Letrozole (letrozole)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Low-Grade Serous Ovarian Cancer | Phase 2 | Status: RECRUITING